On 02 March 2017, Pracelo signed an agreement on the co-financing for the implementation of the project entitled: “The production of adipose tissue-derived allogeneic mesenchymal stem cells as compliant with the requirements of Good Manufacturing Practice – an active substance for the investigational medicinal product for advanced-therapy veterinary use, intended for clinical trials in the treatment of degenerative changes of joints and dysplasia in dogs”, within the framework of the Smart Growth Operational Programme 2014-2020, Measure 1.1 “R&D Projects of Enterprises”. The total cost of the project is PLN 4 520 762.90.
The implementation of the project will make it possible to secure a sustainable competitive advantage, which should in turn result in the company gaining a dominant position on the target market.
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...
ArticleForbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...
ArticleAccording to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...
ArticleGazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...
ArticleWe create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...
Article
